Merrimack Pharmaceuticals, a biopharmaceutical company with an initial focus on cancer treatments, filed on Friday with the SEC to raise up to $173 million in an initial public offering. The Cambridge, MA-based company, which was founded in 1993 and booked $23 million in sales for the 12 months ended March 31, 2011, plans to list on the NASDAQ under the symbol MACK. J.P. Morgan is the lead underwriter on the deal. No pricing terms were disclosed.
